RxDoctor Payments Data

Hitesh Kapupara, MD

Nephrology · Atlantis, FLNPI 1538321021

Payments from drug & device makers

$2,035in general payments, 2019–2025

Across 55 payments — averaging $37.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$374
  • AstraZeneca$331
  • Travere Therapeutics, Inc.$297
  • Bayer$280
  • Otsuka America Pharmaceutical, Inc.$180
  • GSK$141
  • plus $432 from 9 others

What the payments were for

  • Food & beverage$1,94395%
  • Education$925%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,035 in reported general payments places this provider in the 50th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$397,695
Medicare patients
681
Services billed
3,743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol173$197,164
JardianceEmpagliflozin76$100,600
VelphoroSucroferric Oxyhydroxide25$72,013
KerendiaFinerenone20$30,015
EntrestoSacubitril/Valsartan15$15,728
VeltassaPatiromer Calcium Sorbitex17$11,859
Lanthanum Carbonate12$6,650
LokelmaSodium Zirconium Cyclosilicate13$5,492
Potassium Citrate ErPotassium Citrate34$3,002
Sevelamer Carbonate46$2,524
Losartan Potassium217$2,409
Calcium Acetate22$1,727
Bumetanide35$1,277
Nifedipine ErNifedipine46$1,124
Hydralazine Hcl83$787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$331$202,656186 claims
Fresenius USA Marketing, Inc.Velphoro$109$72,01325 claims
BayerKerendia$280$30,01520 claims
NovartisEntresto$17$15,72815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 756 nephrology providers in Florida.

Other nephrology in Atlantis

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →